Point principaux de la réunion du comité d’évaluation des risques en matière de pharmacovigilance (PRAC) 11 – 14 janvier 2021
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-11-14-january-2021
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-11-14-january-2021
https://www.ema.europa.eu/en/documents/other/questions-answers-signal-management_en.pdf
https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-23-26-november-2020-prac-meeting_en.pdf
https://www.gov.uk/guidance/periodic-benefit-risk-evaluation-reports-for-medicinal-products#history
https://www.gov.uk/guidance/send-and-receive-information-on-adverse-drug-reactions-adrs
https://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Questions_Answers/CMDh_257_2012_Rev23_2020_12_clean_QA_on_PhV.pdf
https://www.gov.uk/guidance/guidance-on-mah-and-qppv-location-from-1-january-2021
https://www.swissmedic.ch/swissmedic/fr/home/news/mitteilungen/neue_meldewege_nebenwirkungsmeldungen.html
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency